General Information

We are a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. We designed our NeXT Platform to adapt to the complex and evolving understanding of cancer, providing our biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover roughly 50 to 500 genes. We are also developing a complementary liquid biopsy assay that analyzes all human genes versus the more narrowly focused liquid biopsy assays that are currently available.

Employees: 147
Founded: 2011
Contact Information
Address 1330 O’Brien Drive, Menlo Park, CA 94025, US
Phone Number (650) 752-1300
Web Address
View Prospectus: Personalis
Financial Information
Market Cap $505.8mil
Revenues $47.7 mil (last 12 months)
Net Income $-20.2 mil (last 12 months)
IPO Profile
Symbol PSNL
Exchange NASDAQ
Shares (millions): 7.9
Price range $17.00 - $17.00
Est. $ Volume $134.7 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ Cowen and Company
CO-Managers Oppenheimer & Co.
Expected To Trade: 6/20/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change